ArticleOncology reports2026
Effect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non‑small cell lung cancer cells.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in non‑small cell lung cancer (NSCLC) and is associated with aggressive tumor behavior and poor patient prognosis. However, the molecular mechanisms through which EZH2 drives NSCLC progression, particularly its interplay with major oncogenic signaling cascades, remain incompletely defined. EZH2 expression was analyzed using publicly available databases. Functional perturbations were achieved via short hairpin RNA (shRNA)‑mediated knockdown in NCI‑H1299 and A549 NSCLC cell lines. Cell proliferation, migration, invasion, apoptosis, and colony formation were assessed using Cell Counting Kit‑8, Transwell, flow cytometry and colony formation assays, respectively. Involvement of the JAK2/STAT3 pathway was examined by western blotting and rescue experiments using a JAK2 agonist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.